PL EN


Preferences help
enabled [disable] Abstract
Number of results
2015 | 15 | 1 | 38–40
Article title

Psychotic symptoms due to topiramate

Content
Title variants
EN
Objawy psychotyczne wywołane stosowaniem topiramatu
Languages of publication
EN PL
Abstracts
EN
Topiramate is an antiepileptic drug prescribed in the treatment of numerous psychiatric disorders and in epilepsy. Topiramate exerts its antiepileptic effect through different mechanisms, such as by the blockage of sodium channels, increasing GABAergic neurotransmission, antagonizing excitatory amino acid receptors (glutamate) or blocking calcium channels. Its prescription in psychiatric diseases has increased in recent years and psychotic symptom development due to the usage of topiramate has been observed in some studies. Therefore, it is essential to evaluate the patient for psychotic symptoms while using topiramate. This article presents a case of a 37-year-old woman who developed depression, anxiety and auditory hallucinations during the treatment with 150 mg of topiramate. After stopping topiramate, 5 mg of olanzapine bid was started and the symptoms gradually decreased and finally disappeared.
PL
Topiramat to lek przeciwdrgawkowy przepisywany w leczeniu wielu zaburzeń psychicznych i padaczce. Mechanizm działania przeciwdrgawkowego jest wielokierunkowy – np. lek ten blokuje kanały sodowe, stymuluje neurotransmisję w układzie GABA-ergicznym, antagonizuje receptory dla pobudzających aminokwasów (glutaminian) oraz blokuje kanały wapniowe. Jakkolwiek w ostatnich latach topiramat przepisywany jest coraz częściej w leczeniu zaburzeń psychicznych, to jednak w kilku badaniach zgłaszano występowanie objawów psychotycznych w następstwie jego stosowania. Z tego względu szczególnie ważna jest ocena pacjentów stosujących ten lek pod kątem występowania objawów psychotycznych. Autorzy przedstawiają przypadek 37-letniej pacjentki, u której w związku z leczeniem z użyciem 150 mg topiramatu rozwinęły się depresja, zaburzenia lękowe i omamy słuchowe. Po odstawieniu topiramatu zalecono stosowanie 5 mg olanzapiny dwa razy dziennie. Objawy stopniowo zanikały, aż do całkowitego ustąpienia.
Discipline
Publisher

Year
Volume
15
Issue
1
Pages
38–40
Physical description
Contributors
author
  • Department of Psychology, Faculty of Science and Letters, Canik Başarı University, Samsun, Turkey
  • Department of Psychiatry, Akdeniz University, School of Medicine, Antalya, Turkey
  • Private Practice, Samsun, Turkey
author
References
  • Alderman CP, McCarthy LC, Condon JT et al.: Topiramate in combat- related posttraumatic stress disorder. Ann Pharmacother 2009; 43: 635–641.
  • Evers S: Treatment of migraine with prophylactic drugs. Expert Opin Pharmacother 2008; 9: 2565–2573.
  • Evers S, Afra J, Frese A et al.; European Federation of Neurological Societies: EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol 2009; 16: 968–981.
  • Kanner AM, Wuu J, Faught E et al.; PADS Investigators: A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 2003; 4: 548–552.
  • Khan A, Faught E, Gilliam F et al.: Acute psychotic symptoms induced by topiramate. Seizure 1999; 8: 235–237.
  • Kober D, Gabbard GO: Topiramate-induced psychosis. Am J Psychiatry 2005; 162: 1542.
  • Lieb K, Völlm B, Rücker G et al.: Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 2010; 196: 4–12.
  • Lung FW, Liu CL, Wang CS et al.: Adjunctive topiramate treatment for a refractory familial adolescent mania. World J Biol Psychiatry 2009; 10: 74–77.
  • McElroy SL, Guerdjikova AI, Martens B et al.: Role of antiepileptic drugs in the management of eating disorders. CNS Drugs 2009; 23: 139–156.
  • Miller J, Roache J: Benefits of topiramate treatment in a dual-diagnosis patient. Psychosomatics 2009; 50: 426–427.
  • Mula M, Monaco F: Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord 2009; 11: 1–9.
  • Mula M, Trimble MR, Sander JW: Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 2007; 48: 2322–2326.
  • Ortho-McNeil Pharmaceutical, Inc. Raritan, NJ 08869, 1999. Revision Date: June 2003.
  • Pasini A, Pitzianti M, Baratta A et al.: Timing and clinical characteristics of topiramate-induced psychosis in a patient with epilepsy and tuberous sclerosis. Clin Neuropharmacol 2014; 37: 38–39.
  • Taylor FR: Weight change associated with the use of migraine-preventive medications. Clin Ther 2008; 30: 1069–1080.
  • Winum JY, Poulsen SA, Supuran CT: Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Med Res Rev 2009; 29: 419–435.
  • Zesiewicz TA, Tullidge A, Tidwell J et al.: Topiramate-induced psychosis in patients with essential tremor: report of 2 cases. Clin Neuropharmacol 2006; 29: 168–169.
Document Type
review
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-6fb518a6-1717-498a-a36b-1bb13b2c6c49
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.